Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.56 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.56 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.56 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143282 | 0.85 | ALDH1A1 (0.64) | CNR1ALDH1A1LMNAMAPT | |
| SCHEMBL3529974 | 0.85 | HPGD (0.67) | HPGDCNR1ALDH1A1KDM4EKMT2A | |
| SCHEMBL6435988 | 0.80 | TRPV1 (0.60) | HPGDCNR1ALDH1A1KDM4EKMT2A | |
| SCHEMBL27680999 | 0.79 | HIF1A (0.60) | HPGDCNR1ALDH1A1PLAAT3PLAAT5 | |
| SCHEMBL3283940 | 0.78 | METAP2 (0.60) | HPGDCNR1ALDH1A1KDM4EKMT2A | |
| SCHEMBL22834267 | 0.78 | CNR1 (1.00) | CNR1KDM4EKMT2AMEN1HTT | |
| SCHEMBL29615227 | 0.78 | CNR1 (1.00) | CNR1KDM4EKMT2AMEN1HTT | |
| SCHEMBL1983017 | 0.78 | HPGD (0.56) | HPGDCNR1ALDH1A1KDM4EKMT2A | |
| SCHEMBL1569813 | 0.77 | TRPV1 (0.67) | HPGDCNR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL13034051 | 0.77 | CNR1 (0.57) | HPGDCNR1ALDH1A1KMT2APLAAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5834514-A | INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-11-10 | — | — | US | claimed |
| EP-0758891-A4 | HALOMETHYL AMIDES AS IL-1-g(b) PROTEASE INHIBITORS | SANOFI WINTHROP INC (US) | 1997-12-03 | — | — | EP | claimed |
| EP-0758891-A1 | HALOMETHYL AMIDES AS IL-1$g(b) PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-02-26 | — | — | EP | claimed |
| WO-1995029672-A1 | HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| EP-1806346-B1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5834514-A | INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | HPGD 219/4885CNR1 625/4885ALDH1A1 245/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | HPGD 224/4885CNR1 769/4885ALDH1A1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.